Literature DB >> 27665938

Center-based patient care enhances survival of elderly patients suffering from peripheral arterial disease.

Clemens Höbaus1, Carsten Thilo Herz1, Florian Obendorf1, Marie-Therese Howanietz1, Thomas Wrba2, Renate Koppensteiner1, Gerit-Holger Schernthaner1.   

Abstract

OBJECTIVES: Recent advances in catheter-based intervention in patients with symptomatic peripheral arterial disease (PAD) have halved mortality. Mortality of PAD patients still remains high compared to other clinical forms of atherosclerosis. Intensified patient care might increase adherence to medical management and benefit the survival of PAD patients.
METHODS: Two patient cohorts were compared in a longitudinal prospective follow-up study. 370 PAD patients were included in the intensified center-based vascular medicine group (VMC group) and 332 PAD patients were treated by their usual primary care physician (PCP group). Survival in both groups was compared by Kaplan-Meier and Cox-regression analyses after 5 years.
RESULTS: Survival of patients in the VMC group was 90.8% compared to 66% in the PCP group. Thus, survival was improved by 24.9% by center-based care (absolute risk CI: 19-30.7%; 38% relative risk). PCP treatment increased all-cause mortality by a hazard ratio of 3.7 (95% CI: 2.5-5.5; p < .001). Mortality in the VMC group was significantly associated with the non-modifiable risk factors age, C-reactive protein, and nephropathy in multivariable analyses.
CONCLUSION: These data imply that multi-morbid elderly PAD patients still benefit by intensified specialist care compared to the usual primary care setting. KEY MESSAGES Center-based patient care improves survival in patients with peripheral arterial disease; mortality was reduced from 82 to 21 events per 1000 patient-years (rate ratio 0.26). Mortality was related to age (HR 1.46), CRP (HR 1.36), and nephropathy (HR 2.7). A multifactorial approach combining adequate drug prescription, accomplishment of agreed goals and repetitive training to initiate, implement, and persist treatment adaptations was applied.

Entities:  

Keywords:  Type 2 diabetes mellitus; mortality; patient education; peripheral arterial disease

Mesh:

Year:  2016        PMID: 27665938     DOI: 10.1080/07853890.2016.1241428

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  5 in total

1.  Rehabilitative Exercise Reduced the Impact of Peripheral Artery Disease on Vascular Outcomes in Elderly Patients with Claudication: A Three-Year Single Center Retrospective Study.

Authors:  Fabio Manfredini; Nicola Lamberti; Franco Guerzoni; Nicola Napoli; Vincenzo Gasbarro; Paolo Zamboni; Francesco Mascoli; Roberto Manfredini; Nino Basaglia; María Aurora Rodríguez-Borrego; Pablo Jesús López-Soto
Journal:  J Clin Med       Date:  2019-02-07       Impact factor: 4.241

2.  Peripheral arterial disease and type 2 diabetes: Older patients still exhibit a survival benefit from glucose control.

Authors:  Clemens Höbaus; Carsten Thilo Herz; Thomas Wrba; Renate Koppensteiner; Gerit-Holger Schernthaner
Journal:  Diab Vasc Dis Res       Date:  2020 Mar-Apr       Impact factor: 3.291

3.  Soluble urokinase-type plasminogen activator receptor predicts peripheral artery disease severity and outcomes.

Authors:  Clemens Höbaus; Martin Ursli; Sarah Mohammed Yussef; Thomas Wrba; Renate Koppensteiner; Gerit-Holger Schernthaner
Journal:  Vasc Med       Date:  2021-01-15       Impact factor: 3.239

4.  Impact of the coronavirus disease 2019 pandemic on an academic vascular practice and a multidisciplinary limb preservation program.

Authors:  Elizabeth M Lancaster; Bian Wu; James Iannuzzi; Adam Oskowitz; Warren Gasper; Shant Vartanian; Elizabeth Wick; Jade Hiramoto; Charles Eichler; Errol Lobo; Alexander Reyzelman; Linda Reilly; Julie A Sosa; Michael S Conte
Journal:  J Vasc Surg       Date:  2020-09-12       Impact factor: 4.268

5.  Vascular peroxidase 1 is independently associated with worse kidney function in patients with peripheral artery disease.

Authors:  Lavinia Costas; Carsten Thilo Herz; Clemens Höbaus; Renate Koppensteiner; Gerit-Holger Schernthaner
Journal:  J Nephrol       Date:  2020-08-19       Impact factor: 3.902

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.